Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 (COVID-Lambda)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04331899 |
Recruitment Status :
Completed
First Posted : April 2, 2020
Results First Posted : April 22, 2021
Last Update Posted : November 30, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 | Drug: Peginterferon Lambda-1a Other: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | An open-label, single-blind randomized controlled trial. Study participants will be randomly assigned 1:1 to a single subcutaneous dose of Peginterferon Lambda-1a or placebo along with the standard of care. |
Masking: | Single (Participant) |
Masking Description: | Single-blind study in which only patients are blinded. |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19 |
Actual Study Start Date : | April 25, 2020 |
Actual Primary Completion Date : | August 14, 2020 |
Actual Study Completion Date : | May 6, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Study drug Peginterferon Lambda-1a
Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
|
Drug: Peginterferon Lambda-1a
Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care |
Placebo Comparator: Placebo injection
Study participants will receive a placebo along with the standard of care treatment.
|
Other: Placebo
Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection |
- Duration Until Viral Shedding Cessation [ Time Frame: Assessed for up to 28 days ]Time to first of two consecutive negative respiratory secretions obtained by oropharyngeal and/or anterior nare swabs for SARS-CoV-2 by qRT-PCR.
- Change in Sars-CoV-2 Viral Load [ Time Frame: baseline, day 14 ]Log10 Oropharyngeal viral load over time, mean change at day 14 (SD). Sars-CoV-2 RNA level in oropharyngeal and/or anterior nare swabs collected daily.
- Area Under the Curve of SARS-COV-2 Viral Load [ Time Frame: baseline through day 14 ]Log10 viral load area under the curve through day 14, median (IQR). Area under the curve of SARS-CoV-2 viral load in oropharyngeal and/or anterior nare swabs collected daily.
- Duration Until Resolution of Symptoms [ Time Frame: Up to 28 days ]Duration until resolution of symptoms in days, median (95% CI). Time to alleviation of all symptoms (fever, chills, cough, nasal congestion, muscle pains), defined as the time from initiation of treatment until all symptoms are rated as absent or mild in symptomatic patients.
- Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment [ Time Frame: 28 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years and ≤ 75 years at the time of the assessment
- Able and willing to understand the study, adhere to all study procedures, and provide written informed consent
-
Diagnosis of COVID-19 disease:
- If symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours from swab to the time of commencing informed consent:
- If asymptomatic, initial diagnosis of SARS-CoV-2 infection with positive FDA-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent
Exclusion Criteria:
- Patients who are hospitalized for inpatient treatment or currently being evaluated for potential hospitalization at the time of initiation of informed consent
- Patients with a known allergy to Peginterferon Lambda-1a or any component thereof
- Display symptoms of respiratory distress (Respiratory rate >20, room air oxygen saturation of <94%.)
- Participation in a clinical trial with or use of any investigational agent within 30 days before screening
- Treatment with interferons (IFN) within 12 months before screening
- Previous use of Peginterferon Lambda-1a
- History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication.
- Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant.
- Current or previous history of decompensated liver disease (Child-Pugh Class B or C) or hepatocellular carcinoma
- Co-infected with human immunodeficiency virus (HIV)
- Significant abnormal laboratory test results at screening.
- Other significant medical condition that may require intervention during the study
-
Concurrent use of any of the following medications:
- Therapy with an immunomodulatory agent
- Current use of heparin or Coumadin
- Received blood products within 30 days before study randomization
- Use of hematologic growth factors within 30 days before study randomization
- Systemic antibiotics, antifungals, or antivirals for treatment of active infection within 24 hours before study randomization
- Any prescription or herbal product that is not approved by the investigator
- Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor
- Receipt of systemic immunosuppressive therapy within 3 months before screening

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04331899
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Upinder Singh | Professor (Medicine-Infectious Diseases) |
Documents provided by Stanford University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Stanford University |
ClinicalTrials.gov Identifier: | NCT04331899 |
Other Study ID Numbers: |
55619 |
First Posted: | April 2, 2020 Key Record Dates |
Results First Posted: | April 22, 2021 |
Last Update Posted: | November 30, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Sharing of generated and analyzed datasets. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository |
Access Criteria: | Full access |
URL: | https://purl.stanford.edu/hc972ys6733 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |